Last $6.49 USD
Change Today +0.34 / 5.53%
Volume 574.4K
ICEL On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

cellular dynamics internatio (ICEL) Snapshot

Open
$6.18
Previous Close
$6.15
Day High
$6.70
Day Low
$5.94
52 Week High
01/13/14 - $22.49
52 Week Low
12/12/14 - $4.72
Market Cap
102.6M
Average Volume 10 Days
138.2K
EPS TTM
$-2.01
Shares Outstanding
15.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLULAR DYNAMICS INTERNATIO (ICEL)

Related News

No related news articles were found.

cellular dynamics internatio (ICEL) Related Businessweek News

No Related Businessweek News Found

cellular dynamics internatio (ICEL) Details

Cellular Dynamics International, Inc. develops and manufactures human cells in the United States of America, Europe, Japan, and internationally. The company’s proprietary iCell Operating System comprises human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs), and custom iPSCs and iCell products (MyCell products). It offers iCell Cardiomyocytes, which are purified human heart cells that beat in a dish and behave just like the heart cells found in the human body for in vitro drug discovery, toxicity testing, and chemical safety, as well as in vivo cellular therapeutics research and development, and stem cell banking; and iCell Neurons that are purified human neurons typical of the forebrain for pre-clinical drug discovery, neurotoxicity testing, and disease modeling for Alzheimer’s diseases, Parkinson’s diseases, Huntington’s diseases, and others. The company also provides iCell Endothelial cells, which are interior surface blood vessel cells for use in vascular biology research, such as angiogenesis, atherosclerosis, inflammation, and other life science research; and iCell Hepatocytes that are human liver cells for pre-clinical drug discovery, hepatotoxicity testing, disease modeling, and other life science research. In addition, it offers MyCell products for making iPSCs for stem cell banking, cell modeling of specific ethnic or disease populations, and genetic engineering for in vitro research; and media and reprogramming kits for making iPSCs for limited research use. The company serves biopharmaceutical companies, government research institutions, academic and nonprofit research institutions, contract research organizations, and stem cell banks. Cellular Dynamics International, Inc. was founded in 2004 and is headquartered in Madison, Wisconsin.

128 Employees
Last Reported Date: 03/11/14
Founded in 2004

cellular dynamics internatio (ICEL) Top Compensated Officers

Founder, Chairman of the Board and Chief Exec...
Total Annual Compensation: $475.0K
Founder, Vice Chairman and President
Total Annual Compensation: $475.0K
Chief Operating Officer and Vice President of...
Total Annual Compensation: $360.0K
Chief Commercial Officer and Vice President o...
Total Annual Compensation: $344.0K
Compensation as of Fiscal Year 2013.

cellular dynamics internatio (ICEL) Key Developments

Cellular Dynamics International, Inc. Appoints Susan A. Willetts as Director

Cellular Dynamics International, Inc. announced that Susan A. Willetts was elected to the company's board of directors, effective November 6, 2014. Ms. Willetts also will serve as a member of the company board's audit committee. Ms. Willetts has been an advisory director of Goldman, Sachs & Co. since July 2011. Prior to July 2011 she was a partner. She joined the firm in the Investment Banking Division in 1989, was named managing director in 1996 and partner in 2002. Prior to joining Goldman Sachs, Ms. Willetts worked at Microdot for five years, most recently as treasurer, and at Northwest Industries for three years. She is on the board of the Chicago Botanic Garden, where she served as chair from 2009 to 2012. Ms. Willetts has been a member of the Economic Club of Chicago since 2004 and became a member of The Chicago Network in 2008. She served on the board of The Field Museum from 1998 to 2006.

Cellular Dynamics International Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Cellular Dynamics International reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the period total revenues were $3,567,000 against $2,523,000 a year ago. Loss from operations was $7,808,000 against $7,160,000 a year ago. Net loss was $8,150,000 or $0.52 basic and diluted per share against $7,498,000 or $0.62 basic and diluted per share a year ago. For the nine months, total revenues were $10,143,000 against $7,725,000 s year ago. Loss from operations was $23,840,000 against $17,896,000 a year ago. Net loss was $24,826,000 or $1.58 per basic and diluted share against $18,245,000 or $3.49 per basic and diluted share a year ago.

Cellular Dynamics International, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 04:00 PM

Cellular Dynamics International, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 04:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Emile F. Nuwaysir, Chief Operating Officer and Vice President of Research & Development, Manufacturing & Quality Systems.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICEL:US $6.49 USD +0.34

ICEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cellectis €12.35 EUR -0.18
General Electric Co $25.62 USD +0.48
Lonza Group AG SFr.109.70 CHF -1.50
Sigma-Aldrich Corp $136.51 USD +0.01
View Industry Companies
 

Industry Analysis

ICEL

Industry Average

Valuation ICEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.2x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLULAR DYNAMICS INTERNATIO, please visit www.cellulardynamics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.